Summary

for people ages 18 years and up (full criteria)
at UCSD UCLA
study started
estimated completion:

Description

Summary

The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer

Official Title

A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)

Keywords

Advanced Cancer Carcinoma, Non-Small-Cell Lung Nivolumab Dasatinib Antibodies, Monoclonal Relatlimab Ipilimumab BMS-986205 Nivolumab & Dasatinib Nivolumab & Relatlimab Nivolumab & Ipilimumab Nivolumab & BMS-986205

Eligibility

For people ages 18 years and up

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Advanced Non Small Cell Lung Cancer (NSCLC)
  • Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1
  • Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment
  • Must have at least 1 lesion with measurable disease

Exclusion Criteria:

  • Subjects with certain mutations that have not been treated with a targeted therapy prior to enrollment
  • Subjects who need daily oxygen therapy
  • People with autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply

Locations

  • University of California San Diego (UCSD) accepting new patients
    La Jolla California 92093 United States
  • University of Californa, Los Angeles (UCLA) accepting new patients
    Los Angeles California 90095 United States
  • Cedars-Sinai Medical Center accepting new patients
    Los Angeles California 90048 United States
  • Hoag Memorial Hospital Presbyterian accepting new patients
    Newport Beach California 92658 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Bristol-Myers Squibb
Links
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Investigator Inquiry Form
FDA Safety Alerts and Recalls
ID
NCT02750514
Phase
Phase 2
Study Type
Interventional
Last Updated